コンパニオンアニマル医薬品の市場規模、シェア、成長分析：コンパニオンアニマル別、薬剤クラス別、流通チャネル別、地域別 - 産業予測 2025～2032年

コンパニオンアニマル医薬品市場規模は2023年に158億米ドルとなり、2024年の168億7,000万米ドルから2032年には285億6,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは6.8%で成長する見通しです。

世界のコンパニオンアニマル医薬品市場は、ペット飼育の急増、ペットヘルスケアに対する意識の高まり、動物用医薬品の進歩に後押しされて活況を呈しています。ペットを飼う家庭が増えるにつれて、犬、猫、その他の動物用の医薬品や治療に対する需要は増加の一途をたどっています。主な成長促進要因としては、予防接種と寄生虫駆除を含む予防医療の重視の高まりと、慢性疾患に対する多様な治療ソリューションが挙げられます。さらに、風味をつけた錠剤や外用剤など、ドラッグ・デリバリー・システムの革新により、飼い主の投薬管理が改善されています。ペットの健康が最優先されつつある現在、市場セグメンテーションは持続的な成長を遂げようとしており、製薬企業や獣医師にとって、この拡大する市場に参入する貴重な機会となっています。

目次

イントロダクション

• 調査の目的
• 調査範囲
• 定義

調査手法

• 情報調達
• 二次と一次データの方法
• 市場規模予測
• 市場の前提条件と制限

エグゼクティブサマリー

• 世界市場の見通し
• 供給と需要の動向分析
• セグメント別機会分析

市場力学と見通し

• 市場概要
• 市場規模
• 市場力学
  • 促進要因と機会
  • 抑制要因と課題
• ポーターの分析

主な市場の考察

• 重要成功要因
• 競合の程度
• 主な投資機会
• 市場エコシステム
• 市場の魅力指数（2024年）
• PESTEL分析
• マクロ経済指標
• バリューチェーン分析
• 価格分析
• 規制分析
• 特許分析

コンパニオンアニマル医薬品市場規模：コンパニオンアニマル別

• 市場概要
• 犬
• 猫
• 馬
• その他

コンパニオンアニマル医薬品市場規模：薬剤クラス別

• 市場概要
• 抗生物質
• 抗炎症
• 心臓虫薬
• 寄生虫駆除剤
• 栄養薬
• 行動薬
• ワクチン
• その他

コンパニオンアニマル医薬品市場規模：流通チャネル別

• 市場概要
• 動物用薬局
• eコマース
• 小売薬局

コンパニオンアニマル医薬品市場規模

• 北米
  • 米国
  • カナダ
• 欧州
  • ドイツ
  • スペイン
  • フランス
  • 英国
  • イタリア
  • その他欧州地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • 韓国
  • その他アジア太平洋地域
• ラテンアメリカ
  • ブラジル
  • その他ラテンアメリカ地域
• 中東・アフリカ
  • GCC諸国
  • 南アフリカ
  • その他中東・アフリカ

競合情報

• 上位5社の比較
• 主要企業の市場ポジショニング（2024年）
• 主な市場企業が採用した戦略
• 最近の市場動向
• 企業の市場シェア分析（2024年）
• 主要企業の企業プロファイル
  • 企業の詳細
  • 製品ポートフォリオ分析
  • 企業のセグメント別シェア分析
  • 収益の前年比比較（2022～2024年）

主要企業プロファイル

• Zoetis（USA）
• Elanco Animal Health（USA）
• Virbac（France）
• Ceva Sante Animale（France）
• Boehringer Ingelheim（Germany）
• Merck Animal Health（USA）
• Bayer Animal Health（Germany）
• Kemin Industries（USA）
• Hester Biosciences（India）
• Vetoquinol（France）
• Dechra Pharmaceuticals（UK）
• IDEXX Laboratories（USA）
• Mars Petcare（USA）
• Nestle Purina Petcare（Switzerland）
• Hill's Pet Nutrition（USA）
• Boehringer Ingelheim Vetmedica（Germany）
• MSD Animal Health（USA）
• Bayer HealthCare Animal Health（Germany）
• Virbac Animal Health（France）
• Ceva Animal Health（France）

結論と提言

Companion Animal Drugs Market size was valued at USD 15.8 billion in 2023 and is poised to grow from USD 16.87 billion in 2024 to USD 28.56 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global companion animal drugs market is thriving, fueled by the surge in pet ownership, increased awareness of pet healthcare, and advancements in veterinary pharmaceuticals. As more households adopt pets, the demand for medications and treatments for dogs, cats, and other animals continues to rise. Key growth drivers include a heightened emphasis on preventive care-encompassing vaccinations and parasite control-and a diverse range of therapeutic solutions for chronic conditions. Furthermore, innovation in drug formulations and delivery systems, such as flavored tablets and topical applications, has improved medication administration for pet owners. With the ongoing prioritization of pet well-being, the companion animal drugs market is poised for sustained growth, presenting valuable opportunities for pharmaceutical companies and veterinarians to engage this expanding segment.

Top-down and bottom-up approaches were used to estimate and validate the size of the Companion Animal Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Companion Animal Drugs Market Segments Analysis

Global Companion Animal Drugs Market is segmented by Companion Animals, Drug Class, Distribution Channel and region. Based on Companion Animals, the market is segmented into Dogs, Cats, Horses and Others. Based on Drug Class, the market is segmented into Antibiotics, Anti-inflammatory, Heart Worm Drugs,parasiticides, Nutritional Drugs, Behavioral Drugs, Vaccines and Others. Based on Distribution Channel, the market is segmented into Veterinary Pharmacies, E-commerce and Retail Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Companion Animal Drugs Market

The Companion Animal Drugs market is experiencing significant growth driven by advancements in veterinary medicine. These enhancements encompass the creation of more effective diagnostics, treatments, and pharmaceuticals. As a result, the variety of treatment options available is expanding, leading to improved disease management and higher efficacy in therapy. This progress has heightened the demand for advanced medications for companion animals, reflecting a growing recognition of the importance of pet health and well-being. Consequently, the overall landscape of the companion animal drug market is evolving, creating opportunities for innovative solutions to address the medical needs of pets.

Restraints in the Companion Animal Drugs Market

The Companion Animal Drugs market is encountering significant challenges due to the financial strain associated with these medications and treatments. Many consumers are hesitant to invest in their pets' health because of the high costs involved, which can delay or obstruct market adoption. Pet owners, particularly those in low-income areas or with limited budgets, often perceive the prices of these healthcare options as prohibitively expensive. This can deter them from seeking necessary treatments and medications for their pets, ultimately impacting the growth and accessibility of the market for companion animal healthcare solutions.

Market Trends of the Companion Animal Drugs Market

The Companion Animal Drugs market is experiencing a significant trend towards digital health solutions, driven by the integration of advanced data analytics, telehealth services, wearable devices, and mobile applications. This technological shift enables pet owners to remotely monitor their animals' health indicators, fostering better communication with veterinarians and enhancing overall healthcare management. With these innovations, pet owners can efficiently manage medicinal prescriptions and adhere to treatment protocols, ultimately improving pet welfare and satisfaction. As the market continues to embrace these digital solutions, the demand for companion animal drugs is likely to increase, reflecting a broader trend towards personalized and proactive veterinary care.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Analysis
• Patent Analysis

Global Companion Animal Drugs Market Size by Companion Animals & CAGR (2025-2032)

• Market Overview
• Dogs
• Cats
• Horses
• Others

Global Companion Animal Drugs Market Size by Drug Class & CAGR (2025-2032)

• Market Overview
• Antibiotics
• Anti-inflammatory
• Heart Worm Drugs
• Parasiticides
• Nutritional Drugs
• Behavioral Drugs
• Vaccines
• Others

Global Companion Animal Drugs Market Size by Distribution Channel & CAGR (2025-2032)

• Market Overview
• Veterinary Pharmacies
• E-commerce
• Retail Pharmacies

Global Companion Animal Drugs Market Size & CAGR (2025-2032)

• North America (Companion Animals, Drug Class, Distribution Channel)
  • US
  • Canada
• Europe (Companion Animals, Drug Class, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Companion Animals, Drug Class, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Companion Animals, Drug Class, Distribution Channel)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Companion Animals, Drug Class, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Zoetis (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Elanco Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Sante Animale (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer Animal Health (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kemin Industries (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hester Biosciences (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Vetoquinol (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dechra Pharmaceuticals (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IDEXX Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mars Petcare (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nestle Purina Petcare (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hill's Pet Nutrition (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim Vetmedica (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MSD Animal Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer HealthCare Animal Health (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Virbac Animal Health (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ceva Animal Health (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations